Study of Histrelin Subdermal Implant in Patients With Prostate Cancer
A phase 3 trial of Histrelin and Goserelin / leuprolide in Prostate cancer, run by Endo USA Inc., a Keenova Therapeutics Company, completed.
Overview
Study of Histrelin Subdermal Implant in Patients With Prostate Cancer is a phase 3 interventional study registered as NCT01394263 by Endo USA Inc., a Keenova Therapeutics Company, with 59 participants recorded, started 2000-05 and reaching its primary completion in 2001-12. Interventions recorded: Histrelin hydrogel implant, Zoladex goserelin implant. Conditions recorded: Prostate Cancer, Adenocarcinoma of the Prostate.
Linked to the drug Histrelin because the registry names it among its interventions and Prostate cancer among its conditions. Registry record only: no result has been read by an editor.
Similar pages
not linked directly; found by shared links- TrialStudy to Evaluate Efficacy and Safety of Histrelin Subdermal Implant in Men With Advanced Prostate Cancer
Shares Histrelin, Endo (now Keenova Therapeutics and Par Health), Prostate cancer and the tag pipeline.
- TrialFlutamide, Suramin, and Hydrocortisone in Treating Patients With Prostate Cancer
Shares Goserelin / leuprolide (ovarian function suppression), Prostate cancer and the tag pipeline.
- TrialTwo Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial
Shares Histrelin, Goserelin / leuprolide (ovarian function suppression), Prostate cancer and the tag pipeline.
- TrialStandard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
Shares Histrelin, Goserelin / leuprolide (ovarian function suppression), Prostate cancer and the tag pipeline.
- TrialMulti-center Study to Evaluate the Efficacy and Safety of Maintenance Therapy With Valrubicin Versus no Maintenance, in Subjects Treated With Valrubicin Induction for Carcinoma in Situ (CIS) of the Bladder
Shares Endo (now Keenova Therapeutics and Par Health) and the tag pipeline.
- TrialNeoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate Cancer
Shares Goserelin / leuprolide (ovarian function suppression), Prostate cancer and the tag pipeline.
- TrialInvestigation of the Effect of Degarelix in Terms of Prostate Volume Reduction in Prostate Cancer Patients
Shares Goserelin / leuprolide (ovarian function suppression), Prostate cancer and the tag pipeline.
- TrialHormone Therapy With or Without Docetaxel And Estramustine in Treating Patients With Prostate Cancer That is Locally Advanced or At High Risk of Relapse
Shares Goserelin / leuprolide (ovarian function suppression), Prostate cancer and the tag pipeline.